Board Review Bonus 7: Membranous Nephropathy

In this "Board Review Bonus" (BRB) episode, hosts Dr. Kenar Jhaveri and Dr. Koyal Jain deliver a high-yield clinical overview of membranous nephropathy (MN)—a classic, board-favorite cause of nephrotic syndrome. Utilizing a real-world case of a 50-year-old male presenting with heavy proteinuria and severe hypoalbuminemia, they walk through diagnostic dilemmas, pathological clues, and the modern therapeutic landscape. Whether you are studying for the boards or looking to "class-switch" your clinical knowledge from IgG1 to IgG4, this bite-sized episode is packed with essential clinical pearls.

Key Topics Covered:

• Epidemiology & Biopsy Basics: Identifying MN as one of the most common causes of adult nephrotic syndrome. The hosts break down classic pathology features: diffuse GBM thickening on light microscopy, "spikes" on silver stain, granular IgG and C3 immunofluorescence, and subepithelial dense deposits on EM.
• The Antigen Revolution: A review of how the 2009 discovery of anti-PLA2R antibodies on podocytes transformed the diagnosis of primary MN. They also highlight newer antigens to know for the boards, including NELL-1 (associated with malignancy, medications, and lipoic acid), THSD7A (associated with malignancy), and EXT1/EXT2 (associated with lupus).
• Investigating Secondary Causes: Why age-appropriate malignancy screening, medication reviews, and infectious workups (syphilis, hepatitis B and C) are essential even in PLA2R-positive cases. Key biopsy clues like "full house" staining or endothelial tubuloreticular inclusions can help tip you off to a secondary etiology.
• The "Koyal-Kenar" Risk Stratification: Why tracking immunological remission via anti-PLA2R titers is often far more predictive than following proteinuria alone. The hosts outline when to initiate immunosuppression based on GFR decline, severe proteinuria/complications, or stable/rising anti-PLA2R titers.
• Conservative Therapy (The CKD Toolkit): Standard management including low-sodium diets, maximal RAAS blockade, statins (mindful of CNI interactions), SGLT2 inhibitors, and prophylactic anticoagulation (using apixaban or warfarin) when albumin drops below 2.0–2.5 g/dL.
• The Immunosuppressive Toolkit: Navigating the "big three" regimens: the highly effective but complex 6-month Modified Ponticelli Regimen, first-line Rituximab (backed by the MENTOR trial), and Calcineurin Inhibitors (useful as a bridge, but limited by high relapse rates). Plus, a sneak peek at obinutuzumab (the Majesty trial) for deeper B-cell depletion.

Recommended Literature:

• Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
• Fernández-Juárez G, Rojas-Rivera J, van de Logt AE, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
• Scolari F, Delbarba E, Santoro D, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial.
• The MAJESTY Trial (Obinutuzumab vs Tacrolimus in Primary Membranous Nephropathy): ClinicalTrials.gov Identifier: NCT04629248.

Board Review Bonus 6: Alport Syndrome

In this "Board Review Bonus" (BRB) episode, hosts Dr. Kenar Jhaveri and Dr. Koyal Jain provide a comprehensive clinical overview of hereditary nephritis—also known as Alport syndrome—a complex genetic condition with critical renal and extrarenal implications. From a sneaky real-world case of an 18-year-old female presenting with isolated microscopic hematuria to classic textbook syndromic features , our hosts break down the essential knowledge required for both board preparation and clinical practice.

The discussion moves beyond the classic X-linked male phenotype to explore autosomal varieties and why thin basement membrane disease (TBMD) is increasingly viewed as part of the Alport spectrum rather than a purely benign entity. Dr. Jain and Dr. Jhaveri emphasize critical management strategies, highlighting why an accurate diagnosis is vital to protect patients from receiving unnecessary and ineffective immunosuppressive therapies.

Key Topics Covered:

• The Hematuria Differential: Evaluating a young patient with a family history of hematuria, prioritizing Alport syndrome, thin basement membrane disease, and IgA nephropathy.
• Genetics and Inheritance Patterns: A detailed look at mutations in the alpha 3, 4, and 5 chains of type IV collagen, spanning X-linked, autosomal recessive, and autosomal dominant variants.
• Clinical and Extrarenal Manifestations: Identifying the classic trio of kidney involvement, high-pitched sensorineural hearing loss, and ocular abnormalities like anterior lenticonus.
• Biopsy and Pathology Pearls: Differentiating between simple glomerular basement membrane (GBM) thinning and advanced longitudinal splitting ("basket-weave" lamination) on electron microscopy, alongside the utility of pediatric skin biopsies.
• Clinical Management & Pitfalls: Navigating first-line RAAS inhibition and SGLT2 inhibitors while strictly avoiding immunosuppressive regimens for secondary FSGS lesions.
• Transplantation Outcomes: Understanding why Alport syndrome does not recur post-transplant, balanced against the 3% to 4% risk of developing de novo anti-GBM disease in the allograft.

Recommended Literature:

• Consensus statement on guidelines for the care of children and adolescents with Alport syndrome.
• Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.
• Alport Syndrome: Classification and Management

Episode 5: Board Review Bonus: Renal Amyloidosis

In this "Board Review Bonus" (BRB) episode, hosts Dr. Kenar Jhaveri and Dr. Koyal Jain provide a comprehensive clinical overview of amyloidosis—a complex and often enigmatic disease with significant renal implications. From the initial "mushy, smudgy" appearance on light microscopy to the precise measurements of electron microscopy, our hosts break down the essential knowledge required for both board preparation and clinical practice.

The discussion moves beyond the common AL and AA variants to explore rare types like LECT2 and the hereditary forms. Dr. Jain and Dr. Jhaveri emphasize that "the tissue is the issue," highlighting the diagnostic necessity of biopsying the affected organ and the critical role of mass spectrometry in directing therapy.

Key Topics Covered:

• Classification of Amyloidosis: A detailed look at AL, AA, LECT2, and the hereditary variants including ATTR, fibrinogen A alpha-chain, and Apolipoprotein.
• The Diagnostic Workup: Understanding the utility of Congo red staining, the significance of birefringence, and the institutional variability of fat pad biopsies.
• Electron Microscopy (EM) Pearls: A guide to differentiating amyloid fibrils from mimics such as fibrillary GN, immunotactoid GN, and cryoglobulinemia based on diameter and arrangement.
• Clinical Management: Navigating the multidisciplinary approach between nephrology, hematology, and cardiology, including the nuances of RAAS inhibition and diuretic therapy in proteinuric patients.
• Transplantation Outcomes: Evaluating recurrence rates and survival benefits for different amyloid types post-kidney transplant.

Recommended Resources and Literature:

• • Visual Aid: Concept Map: Causes of Renal Amyloidosis – A comprehensive resource for classifying amyloid variants and their underlying triggers (via NephronPower).
  • Dandona P, et al. The amyloidoses: clinical features, diagnosis and treatment. Methodist Debakey Cardiovasc J. 2012 Jul-Sep;8(3):3-7. PMC3487569
  • Panichella G, et al. Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift. Heart Fail Rev. 2024. PMC12308146
  • Moreno-Martínez P, et al. LECT2-associated renal amyloidosis (ALECT2): A case report. Nefrologia. 2018 Jan-Feb;38(1):97-99. PMID: 29254900
  • Benson MD, et al. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Nat Genet. 1993 Mar;3(3):252-5. PMID: 8097946